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We describe the pro-inflammatory and cytotoxic
effects of nitric oxide in vivo in human skin. Nitrite
and ascorbic acid were mixed on the skin of 12
normal volunteers, three times daily, to release nitric
oxide. Exposure to nitric oxide was varied by
randomizing the concentration of nitrite and duration
of application. Nitric oxide treated skin showed
significant increases in cells expressing CD3, CD4,
CD8, CD68, neutrophil elastase, ICAM-1, VCAM-1,
nitrosotyrosine, p53, and apoptotic cells compared
with skin treated with ascorbic acid alone. There
was no significant increase in mast cells. Following
application of nitric oxide there were significantly
fewer CD1a positive Langerhans cells in the epi-
dermis. These appeared to lose dendritic morphology
Nitric oxide (NO) is a locally synthesized messengerwith many physiologic and pathologic activities. Itis synthesized from arginine by isoforms of NOsynthase (NOS) enzymes. The inducible isoformof NO synthase (iNOS) is induced by lipopoly-
saccharide products of bacterial cell walls or by cytokines, notably
tumor necrosis factor α, interferon-γ (Moncada, 1992), interleukin
(IL)-1β (Moncada, 1992), IL-6 (Sawada et al, 1997), IL-8 (Bruch-
Gerharz et al, 1996), and granulocyte–macrophage colony-stimulat-
ing factor (Laskin et al, 1996). Unlike the pmol quantities of NO
produced by constitutive endothelial and neuroneal NOS, iNOS
produces nanomolar concentrations (Anggard, 1994) which are
involved in the immune response to pathogens (Moncada, 1992),
in tumor cell necrosis and in apoptosis (Messmer et al, 1994).
Increased iNOS expression has been found in the skin in psoriasis
(Sirsjo et al, 1996; Ormerod et al, 1998), atopic dermatitis (Rowe
et al, 1997), irritant and allergic contact dermatitis (Ormerod et al,
1997a), lupus erythematosus,1 sunburn-induced erythema,2 and
NO contributes to mustard oil induced neurogenic vasodilation
(Lippe et al, 1993), and carrageenin-induced edema (Ianaro et al,
1994). NO can potentiate Th1 cell responses in carrageenin-
induced inflammation, where increases in IL-1, IL-2, IL-6, and
interferon-γ are inhibited by the L-arginine analog NG-monome-
thyl L-arginine (Ianaro, 1994). NO specifically induced the DR
marker B7-2 on murine macrophages but not other class 2 IA
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and migrate from the epidermis. There was no
significant difference in staining for Ki-67, a marker
related to proliferating cell nuclear antigen, between
active and control skin but staining was greater after
exposure to higher dose nitric oxide than the low
dose. Apoptosis, cytotoxicity, and p53 staining were
relatively greater after 48 h exposure than after 24 h.
These results suggest that nitric oxide is pro-
inflammatory and is toxic to DNA, leading to the
accumulation of p53 and subsequent apoptosis. High-
dose nitric oxide paradoxically led to a smaller
increase in macrophages and T cells than low dose
suggesting an immunosuppressive effect of higher
levels. Key words: acidified nitrite/adhesion molecules/
apoptosis/p53. J Invest Dermatol 113:392–397, 1999
markers suggesting NO to be a costimulatory molecule in antigen
presentation.3 In one study, growth was inhibited by the activation
of NOS in keratinocyte cultures (Heck et al, 1992). NO, however,
also promoted wound healing and keratinocyte proliferation after
ultraviolet B exposure (Benrath et al, 1995), inhibition of cNOS
has also inhibited keratinocyte proliferation (MacNeil et al, 1993).
NO promotes keratinocyte proliferation via the heme oxygenase
pathway (Clark et al, 1997). NO may also contribute to angiogenesis
(Papapetropoulos et al, 1997b; Noiri et al, 1998). Tumor necrosis
factor-α and platelet-activating factor promote endothelial cell
chemotaxis by an NO-dependent pathway (Montrucchio et al,
1997). NO also mediates the endothelial cell mitogenic effect of
vascular endothelial growth factor (Morbidelli et al, 1996) and
transforming growth factor-β1-induced capillary organization
(Papapetropoulos et al, 1997a).
The cytotoxic effects of NO depend on combination of NO
with superoxide to form peroxynitrite (ONOO–). Nitration of
tyrosine, tryptophan, and guanidine and oxidation of sulfydryl
groups and thioethers can occur via newly liberated NO1 and
NO2
1 intermediates. Oxidation of sulfydryl groups leads to dysfunc-
tion of enzymes in the mitochondrial respiratory chain, notably
aconitase and glyceraldehyde-3-phosphate dehydrogenase. Lipid
1Kuhn A, Fehsal P, Lehman P, Ruzicka T, Kolb-Bachofen V: Expression
of inducible nitric oxide synthase (iNOS) in human epidermis of lupus
erythematosus. J Invest Dermatol 107:504, 1996 (abstr.)
2Kuhn A, Fehsel K, Lehman P, Ruzicka T, Kolb-Bachofen V: UVA and
UVB irradiation of normal skin induces time restricted expression of
inducible nitric oxide synthase in keratinocytes. J Invest Dermatol 109:446,
1997 (abstr.)
3Qureshi AA, Lerner EA: Nitric oxide induced B7–2 expression in
murine macrophages. J Invest Dermatol 108:577, 1997 (abstr.)
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oxidation, can lead to disruption and dysfunction of cell membranes.
Peroxynitrite can react directly with nucleic acids prompting DNA
strand breakage (Szabo, 1996a; Zingarelli et al, 1996). This leads
to the induction of wild-type p53 as shown in cultured cells
(Messmer, 1994; Forrester et al, 1996; Ho et al, 1996), which in
turn leads to apoptosis (Messmer, 1994; Brune et al, 1995).
NO also has important immunosuppressive properties. It can
autoregulate IL-1 and IL-6 production from macrophages (Persoons
et al, 1996), IL-2 production, and Th1 proliferation (Taylor-
Robinson, 1997), and inhibit expression of the adhesion molecules
VCAM-1, ICAM-1 (Takahashi et al, 1996), E-selectin (De Caterina
et al, 1995), and P-selectin (Kanwar and Kubes, 1995). In some
models NO suppresses lymphocyte proliferation (Moilanen and
Vapaatalo, 1995; Schwacha and Eisenstein, 1997; Sciorati et al,
1997) and function, especially Th1 cells (Liew, 1995) and natural
killer cell activity has also been inhibited (Ito et al, 1996). NO also
downregulates the expression of major histocompatibility complex
class II antigens (Sicher et al, 1995). NO may be partly responsible
for the immunosuppression observed following ultraviolet light,
possibly through interference with dendritic cell function (Gillardon
et al, 1995).
To examine the pro-inflammatory and anti-inflammatory effects
of NO in vivo we examined the effects of NO on normal human skin.
MATERIALS AND METHODS
To deliver NO to the skin we used an acidified nitrite as NO donor
(Feelish and Stamler, 1996) substituting ascorbic acid to reduce sodium
nitrite to NO (Williams, 1988).
This leads to nitrous acid (1), which rapidly dissociates to form dinitrogen
trioxide (2). With most acids the dinitrogen trioxide dissociates into NO
and NO2 (3) but the key chemical transformation is reduction of the
nitrous anhydride (N2O3) to NO with concurrent oxidation of ascorbic
acid to dehydroascorbic acid, as shown in equation 4. The evolution of
pure NO from ascorbic acid and nitrite reactions has been established
in vitro using the chemiluminescence meter’s (Thermo Environmental
Instruments, Franklin, MA) ability to detect NO and NO2 separately (Fig 1).
In a pilot study of three subjects, reapplication of 0.5% sodium nitrite
with 2% ascorbic acid, three times daily over 48 h produced mild skin
inflammation whereas 5% nitrite with 2% ascorbic acid produced marked
inflammation. In the subjects treated with 5% nitrite, we measured NO
production by chemiluminescence (using the method of Ormerod et al,
1997b) and blood flow by laser Doppler. Erythema, increased blood flow,
and NO production lasted for 60 min and were of a similar magnitude to
that in a psoriatic plaque. Based on these findings, 12 normal volunteers
with no current or recent history of skin disease and taking no medication
were randomized to receive either low-dose (0.5% nitrite) or high-dose
(5% nitrite) NO to their skin and to receive this for either 24 h (three
applications) or 48 h (six applications), see Table I. Two per cent wt/wt
ascorbic acid in aqueous cream was applied to a control site and an active
site, nitrite containing cream being added only to the active site. Both sites
were then occluded with adhesive plastic and the procedure repeated every
Table I. Subjects were randomly allocated to low or high
nitrite and to 24 or 48 h treatment. The resulting
disposition of patients is shown
Duration 0.5% nitrite 5% nitrite
24 h 2 4
48 h 4 2
8 h. The creams were made up freshly on the day of the experiment and
kept refrigerated in view of the instability of ascorbic acid.
The last application of the cream was made 5 h before the assessment
of the response and biopsy to allow the immediate vasodilatory effects of
NO to subside. At each site a spring thickness gauge (Mitotoyu, Tokyo,
Japan) was used to measure skin thickness, a reflectance erythema meter
measured erythema, and 4 mm punch biopsies were taken. The protocol
was approved by the Joint Ethical Committee of Grampian Health Board
and the University of Aberdeen.
Immunohistochemistry was performed using a streptavidin–biotin
method and diaminobenzidine detection. Mouse anti-human monoclonal
antibodies used in immunocytochemistry were CD1a antibodies (1:5,
Becton Dickinson) for detection of Langerhans cells; CD3 antibody (1:20,
Becton Dickinson); CD4 antibody (1:150, Becton Dickinson, Oxford,
U.K.) for T helper cells; CD8 antibodies (1:20 Scottish Antibody Production
Unit) for cytotoxic/suppressor cells; CD54 antibody (1:100, Serotec,
Oxford, U.K.) for ICAM-1; CD68 antibody (1:10, Dako, Ely, Cambs,
U.K.) for macrophages; CD106 antibody (1:100 Serotec) for VCAM-
1; Ki67 antibody 91:400 (Immunotech, Luton, U.K.) associated with
proliferating cell nuclear antigen in proliferating cells; p53 antibody (1:50,
Novacastra, Newcastle on Tyne, U.K.) for wild-type p53; neutrophil
elastase antibody (1:100, Dako) for neutrophils and a rabbit anti-human
polyclonal antibody for nitrosotyosine antibody (1:100, Upstate, Waltham,
MA) for nitrosylated tyrosine. ApopTag Plus in situ nick end labeling
detection kit (Oncor, Gaithersburg, MD) to identify apoptotic cells. DNA
fragmentation leads to nucleosome 39OH DNA ends. These are catalytically
extended in situ using a terminal deoxynucleotidyl transferase to add
digoxygenin-nucleotide residues. Anti-digoxygenin antibody peroxidase
conjugate is then used to label apoptotic nuclei. All staining was performed
on cryostat sections of snap frozen cryopreserved specimens except apoptosis
and neutrophil elastase which were performed on formalin-fixed, paraffin-
embedded material. Appropriate controls, including secondary antibody
alone and omission of primary antibody were negative. No nonimmune
rabbit serum was available for the polyclonal nitrosotyrosine antibody, but
other controls were negative.
Staining was quantitated by computerized image analysis. Briefly, the
image of the section was captured on a purpose-built computer (Seescan,
Cambridge, U.K.) a blinded observer selects a threshold which identifies
the cells as positively stained and places a standard measuring frame on the
test area of the image. A computer algorithm then counts the positively
stained cells within that area. The data were analyzed by Wilcoxon’s test
for paired samples and Kruskal–Wallis’ test for nonparametric analysis of
variance in the multiple independent samples analyzed for effects of dose
and duration. Cell counting was not possible where stains were diffuse and
where morphology of cells was dendritic. In these cases the blinded
observer rated staining on a scale of 0–4 including intermediate 0.5 steps.
RESULTS
The reflectance erythema measurement of the NO-treated sites
was 32.25 6 5.46 (mean 6 SD) significantly higher than the
control sites 18.08 6 5.81 (p 5 0.0022, Wilcoxon’s). Skin-fold
thickness was 5.04 6 0.75 mm in the NO-treated patches, which
was significantly greater than that of control skin 3.25 6 0.54
(p 5 0.0022, Wilcoxon’s). These measures were not significantly
influenced by dose or duration of exposure, except there was a
trend for greater skin fold thickness in the high dose group
(5.4 mm 6 0.21 vs 4.7 mm 6 0.32) (p 5 0.075).
NO-treated skin showed significant increases in cells expressing
CD3, CD4, CD8, CD68, neutrophil elastase, ICAM-1, VCAM-
1, nitrosotyrosine, p53, and cells undergoing apoptosis compared
with control-treated skin (Table I). Apoptag-positive cells were
few in number compared with those showing cloudy swelling.
There were significantly fewer CD1a-positive cells in the epidermis
(Table I) and these could be seen rounding up and dropping out
of the epidermis (Fig 2A). Ki-67 staining, a marker related to
proliferating cell nuclear antigen did not differ significantly between
active and control sites.
Histology of all NO-treated sites showed a significant increase
in edema, endothelial swelling, cloudy swelling of keratinocytes,
and a mixed infiltrate of lymphocytes and neutrophils. These
changes were quantitated on a 0–4 ordinal scale and were similar
in low dose, high dose, short exposure, and long exposure. The
number of mast cells seen in Azure A stained sections was similar
in control- and NO-treated skin (Fig 3J). A cytotoxic effect was
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seen in all keratinocytes that manifested as cloudy swelling (Fig 3G).
When extensive this led to the formation of bullae high in the
epidermis filled with acute inflammatory cells and cells that have
undergone cytotoxic changes with constriction of the nucleus and
cloudy swelling of clear cytoplasm around them (Fig 3H). Only a
minority of these degenerate cells had undergone apoptosis as
judged by staining with ‘‘Apoptag’’ (Fig 3D). Within the epidermis,
there was also an increase in apoptotic cells. Apoptotic cells were
also detected in the dermis, particularly around adnexal structures.
Positive nitrosotyrosine staining around sebaceous glands suggests
that NO was preferentially absorbed through follicles (Fig 3B).
The following effects of dose were noted (Table III). CD4-
positive cells were fewer in the high-dose (280 6 188 cells per
mm2 6 SD) than the low-dose group (936 6 444 p 5 0.02), and
CD68-positive cells were less (379 6 150 per mm2) with high
dose than with low dose (916 6 628, p 5 0.04 Kruskal–Wallis).
Figure 1. Time course of evolution of NO and NO2. The time
course of evolution of NO and NO2 after the mixing of 50 µl of nitrite
cream (0.5% or 5%) and 50 µl ascorbic acid cream (2%) in a 0.5 liter vessel
detected by chemiluminescence.
Figure 2. Immunocytochemistry results. h, high
dose; l, low dose; 1 5 1 d, 2 5 2 d after application.
(A) Control (2), Langerhans cells normally distributed
with dendritic morphology. (B) NO treated (h2)
Langerhans cells are fewer showing loss of dendricity
and apparently migrating from the epidermis (arrow).
(C) Control CD8 (2). (D) NO treated CD8 (h2)
showing increased numbers around vessels and some
epidermotropism. (E) Control CD4 (1). (F) NO
treated CD4 (h1) showing increased numbers around
vessels. (G) Control CD 68 (macrophages) (1). (H)
NO treated CD68 (h1) showing marked increase in
macrophages around appendages and in the epidermis,
including some subcorneal pustules. (I) Control
ICAM-1 (2). (J) NO treated ICAM-1 (h2) showing
upregulation of ICAM-1 in endothelial cells and
keratinocytes. (K) Control VCAM-1 not expressed
(1). (L) NO treated showing upregulation of VCAM-
1(h1) confined to endothelium.
There was a significant increase in Ki-67-positive proliferating
keratinocytes with high dose (152 6 84 cells per mm2 6 SD)
compared with low dose (73 6 19, p 5 0.01, Kruskal–Wallis),
although there was no difference in Ki-67-positive cells between
the control and NO treatments.
‘‘Apoptag’’ staining was significantly greater after 48 h exposure
to NO (14 6 6 cells per 3 mm section) than after 24 h (3.5 6 4.4,
p , 0.005, Kruskal–Wallis). CD4-positive cells also increased more
at 48 h (824 6 463 cells per mm2) than at 12 h (286 6 463, p 5
0.05, Kruskal–Wallis). The difference for p53 (335 6 300 at 48 h
compared with 70 6 112 at 24 h) was not quite significant (p 5
0.07) (Table III). Cloudy swelling tended to be greater in the
longer duration treatment (mean score 2.5 6 0.5 at 48 h vs
1.7 6 0.79 at 24 h) but was not statistically significant (p 5 0.07).
Staining for p53 was noted in the basal layer of the epidermis,
increased with time and correlated with nitrosotyrosine staining
which followed a similar distribution (r 5 0.62 p 5 , 0.0001).
DISCUSSION
The combination of ascorbic acid and nitrite on the skin causes
the release of pure NO. The dose of NO released under the
conditions described was pro-inflammatory. Some cells had wide
variability as indicated (Table II), reflecting wide variability in the
response. The small numbers and introduction of variables of time
and dose may explain this but statistical tests take this variation into
account. The unusual histologic features of the inflammation
provide important clues to the pro-inflammatory role of NO when
generated at high concentrations by iNOS, for example in psoriasis
or in sunburn. Fifteen minutes after application of the acidified
nitrite to normal skin, blood flow was similar to that measured in
a psoriatic plaque (laser Doppler measurements, data not shown).
Peak NO production, 5 min after application of the creams,
measured by the chemiluminescence method described elsewhere
(Ormerod, 1998) (data not shown), was up to 10 times greater
than that measured epicutaneously in psoriasis (Ormerod, 1997b).
Not all the NO released in the skin, however, would be measured
at the surface and proportionately less of the NO applied to the
skin would diffuse into the living epidermis/dermis, and the plateau
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phase of NO release is close to that we found in severe psoriasis.
Physiologic iNOS production would be continuous. In this in vivo
model it is not easy to say if the inflammatory effects are secondary
to cytotoxic tissue injury or are NO specific. If the inflammation
were secondary to cell damage we would expect cytotoxicity to
be greater in the shorter treatment and inflammation to be greater
in the longer treatment group. The opposite was found, however,
cytotoxic changes increased with time, whereas the inflammatory
changes did not. We are not aware of any other studies of the
direct effects of NO on intact viable organs in vivo.
When NO combines with superoxide to form peroxynitrite
(ONOO–) it initiates DNA nicking and leads to DNA cleavage
(Szabo, 1996a,1996b). Although in situ nick end labeling was
significantly increased, only a few cells in the epidermis and dermis
were labeled. Recently it has been shown that keratinocytes are
Figure 3. Further immunocytochemistry results.
Abbreviations as in Fig 2. (A) Control stained for
nitrosated tyrosine (2). (B) NO treated showing
marked nitrosation of tyrosine (h2) in stratum
corneum/hair follicle and increased staining in the
basal layer (arrow). (C) Control skin stained with in
situ nick end labeling (Apoptag) for apoptosis (2).
(D) NO-treated skin stained for apoptosis (h2),
whereas some of the cells showing cloudy swelling
showed increased uptake, only those with apoptotic
morphology (three indicated by arrow) were counted.
(E) Control stained for wild-type p53 (2). (F) NO
treated showing increase in p53 (h2) in the basal and
suprabasal keratinocytes. (G) Hematoxylin/eosin stain
showing numerous keratinocytes exhibiting cloudy
swelling of the nuclei (arrow) (h2). These exceed
apoptosis and were not associated with increased p53
suggesting nonspecific and reversible cytotoxicity.
(H) NO treated, hematoxylin and eosin showing
regular histology (h2) of the inflammation with
perivascular inflammatory response modest spongiosis,
civatte body formation and subcorneal pustules
containing apoptotic inflammatory cells (neutrophils
and macrophages). (I) Control stained with azure A
for mast cells stained violet (arrow) (2). (J) NO treated
stained for mast cells showing no increase in number
(arrow) (h2). (K) Control stained for neutrophil elastase
(1). (L) NO treated showing increased neutrophils (h1)
in the dermis epidermis and in subcorneal pustules.
Table II. The results of quantitation of immunostaining, for all 12 subjects, showing differences in control and
NO-treated skina
Nitric oxide Control
Mean SD Mean SD Significance Wilcoxon’s
Apoptag 12.5 10.1 0.41 1.16 0.0033
Ki67 6.82 3.88 6.62 2.854 0.67
CD3 574.7 396.3 216.1 122.1 0.0186
CD4 608.2 458.2 176.3 149.9 0.0125
CD8 275.7 193.1 122.1 106.1 0.0284
CD68 673.1 542.4 301.4 361.3 0.0044
p53 214.4 266.4 22.08 53.8 0.0029
Neutrophils 569.4 385.9 71 113.1 0.043
ICAM-1 705.9 704.5 201.9 160.9 0.0209
CD1ab 1 – 3.5 – 0.022
Mast cellsb 0 – 1 – 0.0537
Nitrosotyrosineb 4 – 1 – 0.043
VCAM-1b 1.5 – 0 – 0.0357
aFor continuous measurements (computerized cell counting) showing the mean and standard deviation.
bWhere cell counting was difficult, e.g., more diffuse staining/dendritic cells, staining was graded subjectively on a scale of 0–4 and quoted values are medians. Ki-67 was
counted in the epidermis and apoptag-positive cells counted per standard section through a 3 mm punch biopsy. All other counts were done by computerized image analysis
on a fixed standard measuring frame and are expressed as cells per mm2.
extremely resistant to the cytotoxic effects of NO but are more
likely to be killed if the NO is combined with superoxide (Schuy
et al, 1997). Nitrosylation of tyrosine is a marker of peroxynitrite
activity (Szabo, 1996b). Staining for this was superficial, epidermal
and not found at sites of macrophage and neutrophil activity
suggesting that the peroxynitrite formation is not important for the
inflammatory response we observed. Nitrosotyrosine staining was,
however, seen in proximity to the basal layer where p53 was
maximal so peroxynitrite is likely to be involved in DNA damage
in these cells. It seems likely that NO contributes to cytokine and
ultraviolet-induced apoptosis in the epidermis.
The increase in T helper cells and macrophages was greater in
the low-dose subjects and suggests that at lower doses NO can be
pro-inflammatory but at higher doses becomes cytotoxic to the
immunocompetent cells and begins to exert an inhibitory effect.
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Table III. Differences in the 12 actively treated sites founda
Dose Duration
Cell marker 0.5% nitrite 5% nitrite 24 h 48 h
Apoptag 10.5 (7.3) 7.2 (8.2) 3.5 (4.4) 14 (6)****
Ki67 4.6 (1.1) 9.6 (4.5)**** 5.9 (0.3) 7.3 (4.8)
CD3 43.2 (26.7) 28.6 (22.5) 33.7 (21.1) 38.1 (29.9)
CD4 58.5 (25.9) 17.5 (11.0)*** 17.8 (12.1) 51.4 (29)**
CD8 15.9 (12.4) 18.9 (13.2) 11.8 (6.3) 19.9 (13.8)
CD68 57.3 (40.2) 23.8 (9.1)** 28.7 (6.6) 53.2 (43.9)
p53 11.7 (10.6) 15.5 (23.3) 4.38 (6.6) 20.9 (19.2)*
Neutrophils 32.1 (15.7) 39.1 (31.7) 36.4 (24.6) 34.8 (25.9)
ICAM-1 35.5 (18.7) 55.8 (66.5) 22.9 (6.7) 54.7 (51.7)
CD1a** 20.1 (13.9) 22.9 (25.2) 28.1 (22.9) 16.9 (13.9)
Nitrosotyrosinea 3 4 3 4
VCAM-1a 1 2 1.5 1
aDose and duration indicating cells per mm2 (SD), except nitrosotyrosine and VCAM-1 which are on a scale of 0–4.
*p 5 0.07, **p , 0.05, ***p , 0.02, ****p , 0.01.
This has been seen in other biologic systems and may especially be
true of Th1 cells (Liew, 1995; Taylor-Robinson, 1997). iNOS
mutant mice develop significantly stronger Th1 responses with
increased susceptibility to leishmania infections and decreased
inflammatory responses to Leishmania (Wei et al, 1995). In the
human NO inhibited interferon-γ, IL-2, IL-5, IL-10, and IL-4 by
anti-CD3 activated T cells (Bauer et al, 1997). An autoimmune
inflammatory model in mice showed attenuation of vasculitis
but not of glomerulonephritis or arthritis after iNOS knockout
(Gilkeson et al, 1997). Another mechanism facilitating infiltration
with leukocytes following NO may be the activation of metallo-
proteinases (Murrell et al, 1995) which break down basal laminae,
collagen, and cell matrix assisting cell migration and angiogenesis.
The paradoxical suppression of macrophages and T cells in our
higher dose subjects may reflect the immunosuppressive effects of
higher doses of NO for these cells.
In contrast to our in vivo findings of marked induction of ICAM-
1 and moderate increase in VCAM-1 expression, NO has been
reported to inhibit expression of the adhesion cell molecules
VCAM-1 (De Caterina, 1995; Shin et al, 1996), ICAM-1,
E-selectin, and P-selectin (Kanwar, 1995), although this has been
challenged by Cartwright et al (1997) who found no effect of NO.
Also NO induced E-selectin and VCAM-1 expression in endothelial
cells activated by polyinosinic-polycytidylic acid to mimic viral
infection (Faruqi et al, 1997). The contradiction may relate to
intermediate cytokine activation or may be a concentration-
dependent phenomenon.
The pattern of inflammation was unusual in showing a marked
infiltrate of macrophages after only 24 h. We suggest that NO
released from activated macrophages specifically recruits more
macrophages to kill a pathogen or tumor cell. The only feature
that was unchanged by NO was the number of mast cells.
The ability of NO to promote keratinocyte proliferation after
ultraviolet B exposure (Benrath, 1995) has been previously
described. Inhibition of cNOS inhibited keratinocyte proliferation
(MacNeil, 1993). This is of particular interest in the context of the
contribution NO makes to the pathology of psoriasis. Although
we did not find a significant increase in Ki-67-positive proliferating
cells compared with control, the relative increase in the high-dose
group may indicate an influence of NO at higher doses promoting
keratinocyte proliferation and wound repair. The NO-treated skin
shows features in common with several clinical situations. The
cytotoxic changes, p53, and apoptotic changes and migration of
Langerhans cells suggest that NO mediates these aspects of sunburn
and the development of sunburn cells. The subcorneal pustule
formation seen with NO are not unlike those in pustular psoriasis.
The upregulation of ICAM-1, VCAM-1 T cell infiltrate, and
Langerhans cell changes following NO suggest that NO contributes
to these aspects of psoriasis. The response of Langerhans cells to
NO was striking, and as these cells are known to produce NO we
speculate that NO is an important signaling molecule in their
activation. The pro-inflammatory role of NO we demonstrated
in vivo suggests a potential for disease modification by inhibitors of
iNOS and for immunopotentiation by NO donors in the treatment
of skin infections.
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